Medical Doctor Program year 2025 Reported 2019–2025 Source: CMS Open Payments, 2026 publication

Vicki Morrison

Hematology & Oncology Minneapolis, MN Medical Doctor

NPI 1891894424 CMS profile 131191

701 Park Ave, Hcmc, Hematology Oncology Division, Mail Code O1, Minneapolis, MN 55415

Open in the dashboard

General payments

$354,430

332 records reported · program years 2019–2025

Research payments

$0

Paid to them · None reported · program years 2019–2025

Ownership & investment interest

$0

None reported

Research they led as principal investigator

$281,713 paid to institutions, not to them · program years 2021–2023

Through program year 2025, Vicki Morrison of Minneapolis, MN is reported in the CMS Open Payments database as having received $354,430 across 332 general payments and $0 in research payments paid to them. Separately, studies naming them as principal investigator received $281,713 in research payments, paid to institutions rather than to them.

No combined total General, research and ownership are kept apart. Each is reported under its own rules, and ownership is not money that moved at all but the value of a stake held. A meal, a clinical trial grant and a shareholding do not add up to anything meaningful, so this site does not add them. The principal-investigator line is research money paid to institutions for studies they led — not to them — and is not added to anything either.

General payments for this record sit in the 97th percentile of Hematology & Oncology profiles with reported payments. Percentile describes the distribution, not the conduct.

By program year

7 rows
Year Kind Relative to this record's peak year Amount Records
2025 General $10,799 10
2024 General $54,077 57
2023 General $38,249 48
2022 General $77,954 77
2021 General $27,322 24
2020 General $67,234 51
2019 General $78,794 65

Beside peers

Year by year, beside peers General payments · among profiles paid that year
  • Vicki Morrison
  • Hematology & Oncology median
  • Middle half of Hematology & Oncology
  • National median

In program year 2025, general payments to Vicki Morrison were reported at $10,799. Among 8,769 Hematology & Oncology profiles paid that year, the median was $683 and the middle half received between $143 and $3,154.

Show as a table
Year Vicki Morrison Hematology & Oncology median Middle half National median
2019 $78,794 $529 $121–$2,516 $163
2020 $67,234 $339 $82–$2,213 $114
2021 $27,322 $263 $49–$1,965 $132
2022 $77,954 $416 $103–$2,395 $149
2023 $38,249 $542 $125–$2,646 $160
2024 $54,077 $692 $141–$3,008 $164
2025 $10,799 $683 $143–$3,154 $169

Breakdown

Who paid General payments · program years 2019–2025
  1. Celgene Corporation $130,920 100 payments
  2. Lilly USA, LLC $91,403 88 payments
  3. E.R. Squibb & Sons, L.L.C. $51,792 46 payments
  4. Seattle Genetics, Inc. $20,150 16 payments
  5. Kite Pharma, Inc. $16,140 21 payments
  6. Exelixis Inc. $7,839 14 payments
  7. Genentech USA, Inc. $6,010 5 payments
  8. Amgen Inc. $5,280 7 payments
  9. Epizyme, Inc., $5,163 4 payments
  10. Merck Sharp & Dohme Corporation $5,000 4 payments
  11. Other $14,735 27 payments

Every payment, record by record

What the payments were for General payments · program years 2019–2025
  1. Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program $225,308 69 payments
  2. Travel and Lodging $66,271 169 payments
  3. Consulting Fee $54,855 34 payments
  4. Honoraria $3,875 2 payments
  5. Food and Beverage $3,336 55 payments
  6. Compensation for serving as faculty or as a speaker for a non-accredited and noncertified continuing education program $750 1 payment
  7. Education $36 2 payments
Products named General payments · program years 2019–2025
  1. JAYPIRCA $51,055 35 payments
  2. INREBIC Hematology $35,656 26 payments
  3. Revlimid Hematology / Oncology $34,831 26 payments
  4. Pomalyst $31,923 26 payments
  5. Inrebic Myelofibrosis $21,564 16 payments
  6. ADCETRIS $20,150 16 payments
  7. ONUREG $19,048 20 payments
  8. Revlimid Hematology $17,576 16 payments
  9. Yescarta $16,140 21 payments
  10. CABOMETYX $5,859 13 payments
  11. Other $13,866 19 payments

A payment can name more than one product, so these amounts overlap and do not add up to the general-payment figure.

Records

332 reported

Every payment, record by record

Date, company, amount, what it was for and the product named — filter by year, kind and company, or download as CSV.

Related records

What this means

U.S. law requires drug and medical device manufacturers to report payments and transfers of value they make to physicians and teaching hospitals. The Centers for Medicare & Medicaid Services publishes that record each year. This page shows what was reported about this person, and nothing else.

An ownership interest is different from the other two. It is not a payment: it is a stake — shares, options, a partnership holding — that a physician or an immediate family member held in a manufacturer during that year. The figure shown is what the stake was reported to be worth.

Research payments frequently pass through a clinician to the institution running a trial, and rarely represent personal income. They should be read differently from general payments.

Provenance

Source: CMS Open Payments · through program year 2025

Data current to program year 2025, from CMS's 2026 publication.

We reproduce what manufacturers reported. We do not verify, edit or correct the underlying records.

A payment record is not evidence of wrongdoing. Financial relationships between industry and medicine are legal, common and often necessary for research. Who Paid My Doc reports what was disclosed; it does not judge it.

Who Paid My Doc is independent and is not affiliated with, endorsed by or sponsored by CMS or any U.S. government agency. It is not a consumer reporting agency and this is not a consumer report; do not use it for decisions covered by the Fair Credit Reporting Act.

How to dispute or correct a record